Utah Medical Products Inc

Health Care
Medical/Dental Instruments
www.utahmed.com

Earnings Score
Moat Score

Market Cap $219.67M
PE 14
Debt $NaN
Cash $88.45M
EV $NaN
FCF $16.92M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$15.26M
EBIT	$18.21M
ROE	12%
ROA	14%
FCF	$16.92M
Equity	$124.20M
Growth Stability	72%
PE	14.4
PEG	2.05
PB	1.77
P/FCF	12.99
P/S	4.98
Price/Cash	0.4
Net Margins	35%
Gross Margins	59%
Op. Margins	41%
Earnings CAGR	4%
Sales Growth YoY	-20%
Sales Growth QoQ	-4%
Sales CAGR	3%
FCF CAGR	6%
Equity CAGR	8%
Earnings Stability	0.31
Earnings Growth YoY	-9%
Earnings Growth QoQ	3%

Earnings CAGR 5Y	7%
Sales CAGR 5Y	2%
FCF CAGR 5Y	1%
Equity CAGR 5Y	6%
Earnings CAGR 3Y	-3%
Sales CAGR 3Y	-3%
FCF CAGR 3Y	-3%
Equity CAGR 3Y	7%
Market Cap	$219.67M
Revenue	$44.08M
Dividend Yield	2%
Payout Ratio	28%
Assets	$129.69M
Cash	$88.45M
Shares Outstanding	3.44M
Earnings Score	11%
Moat Score	95%
Working Capital	98.22M
Current Ratio	29.59
Gross Profit	$25.92M
Shares Growth 3y	-2%
Equity Growth QoQ	0%
Equity Growth YoY	0%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Utah Medical Products Inc is involved in the business of developing, manufacturing and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.

SEC Filings

Direct access to Utah Medical Products Inc (UTMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Utah Medical Products Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Utah Medical Products Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%

Stability 31%

loading chart...

Utah Medical Products Inc Discounted Cash Flow

Fully customizable DCF calculator online for Utah Medical Products Inc.

Years

Calculation mode

= $262M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$17M	$18M	$19M	$20M	$22M	$23M	$24M	$26M	$28M	$29M	$31M	$313M
DCF		$16M	$16M	$15M	$15M	$14M	$14M	$13M	$13M	$12M	$12M	$121M
Value	$262M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	28%	29%	31%	21%	44%	31%	26%	30%	32%	33%	35%
ROA	-	20%	21%	20%	19%	16%	12%	16%	17%	15%	14%
ROE	-	17%	18%	11%	21%	15%	11%	14%	14%	13%	12%

Good Net Margins (34.56%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	0	-	0	0	0	0	0	0	0	-
Debt over Equity	0.06	0	-	0	0	0	0	0	0	0	-
Growth Stability	-	-	-	72%	100%	100%	78%	100%	100%	100%	72%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (72%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-3%	-2%	5%	1%	12%	-10%	16%	7%	-4%	2%
Earnings YoY growth	-	4%	2%	-30%	118%	-21%	-27%	37%	11%	1%	7%
Equity YoY growth	-	8%	-1%	13%	14%	14%	2%	4%	7%	12%	6%
FCF YoY growth	-	-5%	-18%	36%	7%	1%	17%	7%	-2%	6%	1%